Invega is not recommended for patients with creatinine clearance below 10 mL/min.
Paliperidone is the active metabolite of risperidone (see separate entry).
- TRADE NAME: Invega (Janssen)
- INDICATIONS: Schizophrenia
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: ~23 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Alcohol, Alpha blockers, Amphetamines, Angiotensin II receptor antagonists, Carbamazepine, CNS depressants, Dopamine agonists, Droperidol, General anesthetics, Itraconazole, Levodopa, Levomepromazine, Lithium, Methylphenidate, Metoclopramide, Myleosuppressives, P-glycoprotein inhibitors or inducers, Quinagolide, Risperidone, Tetrabenazine, Valproic Acid
- See adverse reactions attributed to class:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of paliperidone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/13/2025
